News

Providence Cancer Institute researchers share important cancer research at SITC annual meeting and receive recognition for their contributions to science.

Providence and Microsoft Research have developed an AI framework that could revolutionize clinical trials and bring new treatments into play quicker than before.

Over a 10-year period, research shows inhalers produced nearly 25 million metric tons of CO₂ equivalent emissions.

Learn how to take a pilgrimage in your own backyard to reflect on our planet and how you intend to care for it.

Strong culture of unity and service is evident to patients and visitors

New case study shows how a streamlined digital experience improved lab order adherence, reduced no-shows and enhanced operational efficiency at Providence.

Initiative Delivers Scalable Interoperability, Reduces Administrative Burden for Providers and Patients

Providence Cancer Institute leader joined experts in cancer research, policy and advocacy to discuss current challenges and the future of research.

DAX Copilot picks up on ambient conversation and turns it into clinical documentation, preventing caregiver burnout and improving patient care.

Mary E. Brunkow, PhD, a researcher at the Providence-affiliated Institute for Systems Biology, and two colleagues have been awarded the 2025 Nobel Prize in Physiology or Medicine.

Providence medical breast oncologist to give a special presentation on Lobular Breast Cancer and the latest data on the development of a lobular prevention vaccine.

Providence Saint John’s Health Center earns top national honors for providing expert, compassionate stroke care and community education in Los Angeles.

Providence and Compassus announced today they have finalized the second phase of a joint venture for home health, hospice, community-based palliative care and personal home care services in California

A medication designed to block and break down the androgen receptor, a key driver of prostate cancer growth, is being evaluated in a clinical trial at Providence Cancer Institute.

Two new trials evaluating new medications or combinations of medications for people with ovarian cancer or small cell lung cancer open at Providence Cancer Institute.

Our Conversation & Navigation Platform (CNP) uses AI to help patients get answers more quickly and reduce the number of messages our physicians receive.

A phase III clinical trial for people with HR+ HER2- breast cancer aims to extend survival and improve patients’ quality of life.

This is an exciting new trial comparing robotic assisted laparoscopy to open hysterectomy and lymph node assessment for the treatment of early-stage cervical cancer.

Two studies for people with ER+/HER2- breast cancer are enrolling patients at Providence Cancer Institute.